ABUS vs GPC · P/E 5.4, rev $6.2M vs P/E 21, rev $23.49B
Arbutus Biopharma Corp (ABUS) versus Genuine Parts Co (GPC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Genuine Parts Co (GPC) is a auto parts company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GPC revenue for 2024-12-31 was $23.49B. Net income was $904.1M. Revenue was up 1.7% from 2023-12-31 to 2024-12-31. GPC currently screens at market cap $17.60B and trailing P/E 20.7.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GPC currently screens at market cap $17.60B and trailing P/E 20.7.
Not investment advice. Open the ABUS and GPC stock pages for the full models.
Not investment advice.